The global insulin delivery pen market is estimated to record a CAGR of 8.1% from 2024 to 2034. This is likely to take the ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Scientists discover unique insulin responses in each person, opening new paths for early diabetes detection and treatment.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ... Human Monocomponent Insulin, and in 1987, the first human insulin products were made using genetically engineered yeast cells. Novo launched the ...

Offering needle-safe features ... insulin pens made by the three major insulin manufacturers In March 2022, Novo Nordisk announced the launch of its smart insulin pens in the UK, providing diabetes ...

Novo Nordisk ... people needing insulin still had multiple options available in the country. Diabetologist V Mohan said that people who were using the more expensive pen device could shift ...

Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- The "Pen Needles Market by Type (Standard ... Prominent players include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B.

Novo Nordisk has become a global sensation with ... disease into innovative medicines and delivery systems, like insulin pens. The company’s disease portfolio includes diabetes, obesity, and ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...